Skip to content

ADVANZ PHARMA Corp.

Delisted

CIK 1642271fmd_0FTGPRYNYV605B13E61BGHBCHYManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2015 to Dec 31, 2017, 3 periods

Latest annual · FY2017

Millions
Total revenues
626
Gross profit
436
Operating income
(1,165)
Net income
(1,591)
Free cash flow
281
Open Financials

ADVANZ PHARMA Corp. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2017FY2016ChangeSource
Revenue$626.2 million$816.2 million-23.3%20-F 2018-03-08 · proof
Gross profit$435.5 million$595 million-26.8%20-F 2018-03-08 · proof
Operating income-$1.2 billion-$942.3 million20-F 2018-03-08 · proof
Net income-$1.6 billion-$1.3 billion20-F 2018-03-08 · proof
Cash from operating activities$283.2 million$408.3 million-30.6%20-F 2018-03-08 · proof
Free cash flow$280.7 million$406.4 million-30.9%20-F 2018-03-08 · proof
Total assets$2.3 billion$3.7 billion-37.8%20-F 2018-03-08 · proof
Total liabilities$4.2 billion$4.1 billion+3%20-F 2018-03-08 · proof
Cash and cash equivalents$327 million$397.9 million-17.8%20-F 2018-03-08 · proof
Total debt$3.7 billion$3.5 billion+4%20-F 2018-03-08 · proof
What was ADVANZ PHARMA Corp.'s revenue in fiscal 2017?
ADVANZ PHARMA Corp. reported revenue of $626.2 million for fiscal 2017 (the year ended Dec 31, 2017), against $816.2 million the year before (-23.3%). Source: the 20-F filed with the SEC on Mar 8, 2018. SEC
What was ADVANZ PHARMA Corp.'s gross profit in fiscal 2017?
ADVANZ PHARMA Corp. reported gross profit of $435.5 million for fiscal 2017 (the year ended Dec 31, 2017), against $595 million the year before (-26.8%). Source: the 20-F filed with the SEC on Mar 8, 2018. SEC
What was ADVANZ PHARMA Corp.'s operating income in fiscal 2017?
ADVANZ PHARMA Corp. reported operating income of -$1.2 billion for fiscal 2017 (the year ended Dec 31, 2017), against -$942.3 million the year before. Source: the 20-F filed with the SEC on Mar 8, 2018. SEC
What was ADVANZ PHARMA Corp.'s net income in fiscal 2017?
ADVANZ PHARMA Corp. reported net income of -$1.6 billion for fiscal 2017 (the year ended Dec 31, 2017), against -$1.3 billion the year before. Source: the 20-F filed with the SEC on Mar 8, 2018. SEC
What was ADVANZ PHARMA Corp.'s cash from operating activities in fiscal 2017?
ADVANZ PHARMA Corp. reported cash from operating activities of $283.2 million for fiscal 2017 (the year ended Dec 31, 2017), against $408.3 million the year before (-30.6%). Source: the 20-F filed with the SEC on Mar 8, 2018. SEC
What was ADVANZ PHARMA Corp.'s free cash flow in fiscal 2017?
ADVANZ PHARMA Corp. reported free cash flow of $280.7 million for fiscal 2017 (the year ended Dec 31, 2017), against $406.4 million the year before (-30.9%). Source: the 20-F filed with the SEC on Mar 8, 2018. SEC
What are ADVANZ PHARMA Corp.'s total assets?
As of Dec 31, 2017, ADVANZ PHARMA Corp. reported total assets of $2.3 billion, against $3.7 billion a year earlier (-37.8%). Source: the 20-F filed with the SEC on Mar 8, 2018. SEC
What are ADVANZ PHARMA Corp.'s total liabilities?
As of Dec 31, 2017, ADVANZ PHARMA Corp. reported total liabilities of $4.2 billion, against $4.1 billion a year earlier (+3%). Source: the 20-F filed with the SEC on Mar 8, 2018. SEC
What are ADVANZ PHARMA Corp.'s cash and cash equivalents?
As of Dec 31, 2017, ADVANZ PHARMA Corp. reported cash and cash equivalents of $327 million, against $397.9 million a year earlier (-17.8%). Source: the 20-F filed with the SEC on Mar 8, 2018. SEC
What is ADVANZ PHARMA Corp.'s total debt?
As of Dec 31, 2017, ADVANZ PHARMA Corp. reported total debt of $3.7 billion, against $3.5 billion a year earlier (+4%). Source: the 20-F filed with the SEC on Mar 8, 2018. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1642271&period_type=annual&limit=5"

Information only, not investment advice.